ArticleAnnals of the rheumatic diseases2002
Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
Article in Annals of the rheumatic diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00261118 (Phase 3), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis
Who cites it
28 citing papers in PubMed, 134 citations in OpenAlex.
- Rituximab in cryoglobulinemic peripheral neuropathy.Journal of neurology · 2009Trial
- Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.Journal of clinical medicine · 2025Review
- The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Rituximab for the Treatment of Anti-glomerular Basement Membrane Disease with Isolated Diffuse Alveolar Hemorrhage.Internal medicine (Tokyo, Japan) · 2023Article
- Rituximab for the treatment of refractory anti-glomerular basement membrane disease.Renal failure · 2022Article
- [Successful rituximab treatment of recurrent glomerulonephritis associated with antibodies against the glomerular basement membrane].Der Internist · 2020Article
- Antioxidative stress of oral administration of tea extract granule in chickens.Poultry science · 2020Article
- Goodpasture's autoimmune disease - A collagen IV disorder.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease.BMC nephrology · 2018Article
- N-Butyl-2-cyanoacrylate-based injectable and in situ-forming implants for efficient intratumoral chemotherapy.Drug delivery · 2017Article
- Rituximab therapy for primary glomerulonephritis: Report on two cases.World journal of clinical cases · 2015Article
- A unique way to treat Goodpasture's disease.BMJ case reports · 2014Article
- Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy.Clinical kidney journal · 2014Article
- The missing link between smoking and COPD autoreactivity?American journal of respiratory and critical care medicine · 2011Article
- Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.Clinical rheumatology · 2011Review
- Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.Journal of neuro-oncology · 2009Article
- Rituximab in two cases of Goodpasture's syndrome.NDT plus · 2009Article
- A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab.Journal of thrombosis and thrombolysis · 2009Article
- Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.Clinical reviews in allergy & immunology · 2008Review
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.Annals of the rheumatic diseases · 2007Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia. PATIENTS: Because of its novel mechanism of action, rituximab was used to treat three patients with refractory systemic antibody mediated autoimmune disorders. The first patient, a 71 year old woman with idiopathic type II mixed essential cryoglobulinaemia, had both dermatological and neurological manifestations with marked renal disease attributed to her cryoglobulinaemia. Patient 2, a 73 year old woman with Goodpasture's syndrome, was refractory to conventional treatment (cyclophosphamide, prednisone, plasmapheresis). She had persistent haemoptysis and haematuria and positive antiglomerular basement membrane antibodies. The third patient, a 75 year old man with primary biliary cirrhosis, myelodysplasia, and systemic immune complex vasculitis, had progressive renal insufficiency, a macular erythematous rash, and severe thrombocytopenia.
resultsTreatment with rituximab resolved all clinical and laboratory manifestations in the three patients.
conclusionsRituximab may be an important therapeutic agent for the treatment of patients refractory or intolerant to corticosteroid or cytotoxic treatment, or both.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.